For decades, millions of healthy individuals have taken daily low-dose aspirin as a proactive measure against heart attacks and strokes. However, new research is prompting a significant rethink on this long-held practice for those without a prior history of cardiovascular events.
The increased risk of serious bleeding – particularly in the gastrointestinal tract and, more rarely, in the brain – has become a major concern. Studies have shown that older adults and those with certain underlying health conditions are disproportionately affected by these risks. According to the University of Reading's analysis, this trend is alarming, especially for those over 70 who do not have established cardiovascular disease.
The American Heart Association and the American College of Cardiology have recently updated their guidance, advising against routine aspirin use in adults over 70 with no prior heart or stroke events. For individuals aged 40 to 69, healthcare professionals are being urged to carefully weigh individual risk factors before prescribing daily low-dose aspirin for primary prevention.
The National Institute for Health and Care Excellence (NICE) in the UK echoes this approach, recommending a personalised assessment of an individual's cardiovascular risk against the potential bleeding risks. This nuanced approach acknowledges that each person's circumstances are unique and requires a tailored consideration of their needs.
It is essential to distinguish between primary and secondary prevention when it comes to aspirin therapy. For individuals who have already suffered a heart attack, stroke, or established cardiovascular disease, daily aspirin remains an essential medication for reducing the risk of recurrent events.
The shift in guidance underscores the importance of evidence-based medicine and the continuous evolution of medical guidelines to ensure patient safety and optimal health outcomes. As healthcare professionals reassess their approach to aspirin therapy, it will be crucial to engage patients in more detailed discussions about their individual cardiovascular risks and treatment options.
Source: University of Reading